Merck & Co., Inc., Rahway, N.J., USA Financial Highlights Package Fourth Quarter 2025 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 4Q25 and Dec YTD 25........3 Table 2b: GAAP to Non-GAAP Reconciliation 4Q24 and Dec YTD 24........4 Table 3: Sales - Current Year and Prior Year by Quarter..........................5 Table 3a: Sales – U.S. / International 4Q25.................................................6 Table 3b: Sales – U.S. / International Dec YTD 25......................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 16,400 $ 15,624 $ 5% 65,011 $ 64,168 $ 1% Costs, Expenses and Other Cost of sales 5,551 3,828 45% 16,382 15,193 8% Selling, general and administrative 2,898 2,864 1% 10,733 10,816 -1% Research and development 3,886 4,585 -15% 15,789 17,938 -12% Restructuring costs 213 51 * 889 309 * Other (income) expense, net 432 126 * 151 (24) * Income Before Taxes 3,420 4,170 -18% 21,067 19,936 6% Income Tax Provision 458 425 2,804 2,803 Net Income 2,962 3,745 -21% 18,263 17,133 7% Less: Net (Loss) Income Attributable to Noncontrolling Interests (1) 2 9 16 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 2,963 $ 3,743 $ -21% 18,254 $ 17,117 $ 7% Earnings per Common Share Assuming Dilution 1.19 $ 1.48 $ -20% 7.28 $ 6.74 $ 8% Average Shares Outstanding Assuming Dilution 2,488 2,537 2,507 2,541 Tax Rate 13.4% 10.2% 13.3% 14.1% * 100% or greater GAAP % Change 4Q25 4Q24 GAAP % Change Full Year 2025 Full Year 2024 MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 1 -- 2 of 10 -- Sales 15,529 $ 15,806 $ 17,276 $ 16,400 $ 65,011 $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 $ 5% 1% Costs, Expenses and Other Cost of sales 3,419 3,557 3,855 5,551 16,382 3,540 3,745 4,080 3,828 15,193 45% 8% Selling, general and administrative 2,552 2,649 2,633 2,898 10,733 2,483 2,739 2,731 2,864 10,816 1% -1% Research and development 3,621 4,048 4,234 3,886 15,789 3,992 3,500 5,862 4,585 17,938 -15% -12% Restructuring costs 69 560 47 213 889 123 80 56 51 309 * * Other (income) expense, net (35) (7) (238) 432 151 (33) 42 (162) 126 (24) * * Income Before Taxes 5,903 4,999 6,745 3,420 21,067 5,670 6,006 4,090 4,170 19,936 -18% 6% Income Tax Provision 818 571 958 458 2,804 903 545 929 425 2,803 Net Income 5,085 4,428 5,787 2,962 18,263 4,767 5,461 3,161 3,745 17,133 -21% 7% Less: Net Income (Loss) Attributable to Noncontrolling Interests 6 1 2 (1) 9 5 6 4 2 16 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,079 $ 4,427 $ 5,785 $ 2,963 $ 18,254 $ 4,762 $ 5,455 $ 3,157 $ 3,743 $ 17,117 $ -21% 7% Earnings per Common Share Assuming Dilution 2.01 $ 1.76 $ 2.32 $ 1.19 $ 7.28 $ 1.87 $ 2.14 $ 1.24 $ 1.48 $ 6.74 $ -20% 8% Average Shares Outstanding Assuming Dilution 2,531 2,513 2,498 2,488 2,507 2,544 2,544 2,541 2,537 2,541 Tax Rate 13.9% 11.4% 14.2% 13.4% 13.3% 15.9% 9.1% 22.7% 10.2% 14.1% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Full Year 2025 2Q 3Q 4Q Full Year 1Q 1Q 2Q 3Q 2024 4Q 4Q Full Year % Change MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2 -- 3 of 10 -- Fourth Quarter Cost of sales 5,551 $ 1,054 1,173 2,227 3,324 $ Selling, general and administrative 2,898 48 2 50 2,848 Research and development 3,886 5 (111) (106) 3,992 Restructuring costs 213 213 213 – Other (income) expense, net 432 206 206 226 Income Before Taxes 3,420 (1,107) (1,277) (206) (2,590) 6,010 Income Tax Provision (Benefit) 458 (187) (3) (234) (3) (44) (3) (465) 923 Net Income 2,962 (920) (1,043) (162) (2,125) 5,087 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 2,963 (920) (1,043) (162) (2,125) 5,088 Earnings per Common Share Assuming Dilution 1.19 $ (0.37) (0.42) (0.06) (0.85) 2.04 $ Tax Rate 13.4% 15.4% Full Year Cost of sales 16,382 $ 2,871 1,484 4,355 12,027 $ Selling, general and administrative 10,733 120 3 123 10,610 Research and development 15,789 19 175 194 15,595 Restructuring costs 889 889 889 – Other (income) expense, net 151 (3) (306) (309) 460 Income Before Taxes 21,067 (3,007) (2,551) 306 (5,252) 26,319 Income Tax Provision (Benefit) 2,804 (525) (3) (473) (3) 65 (3) (60) (4) (993) 3,797 Net Income 18,263 (2,482) (2,078) 241 60 (4,259) 22,522 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 18,254 (2,482) (2,078) 241 60 (4,259) 22,513 Earnings per Common Share Assuming Dilution 7.28 $ (0.99) (0.83) 0.10 0.02 (1.70) 8.98 $ Tax Rate 13.3% 14.4% Only the line items that are affected by non-GAAP adjustments are shown. (4) Amount represents a net tax benefit, including a net benefit related to favorable audit reserve adjustments. GAAP Acquisition- and Divestiture-Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal Non-GAAP The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales for the fourth quarter and full year reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of inventories related to the Verona Pharma acquisition. Cost of sales for the full year also includes intangible asset impairment charges. For the full year, cost of sales reflects a benefit from a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as contractual termination costs and related adjustments, associated with activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. MERCK & CO., INC., RAHWAY, N.J., USA FOURTH QUARTER AND FULL YEAR 2025 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a 3 -- 4 of 10 -- Fourth Quarter Cost of sales 3,828 $ 701 121 822 3,006 $ Selling, general and administrative 2,864 29 16 45 2,819 Research and development 4,585 12 (1) 11 4,574 Restructuring costs 51 51 51 – Other (income) expense, net 126 (31) 152 121 5 Income Before Taxes 4,170 (711) (187) (152) (1,050) 5,220 Income Tax Provision (Benefit) 425 (111) (3) (17) (3) (33) (3) (260) (4) (421) 846 Net Income 3,745 (600) (170) (119) 260 (629) 4,374 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 3,743 (600) (170) (119) 260 (629) 4,372 Earnings per Common Share Assuming Dilution 1.48 $ (0.23) (0.07) (0.04) 0.10 (0.24) 1.72 $ Tax Rate 10.2% 16.2% Full Year Cost of sales 15,193 $ 2,409 495 2,904 12,289 $ Selling, general and administrative 10,816 117 83 200 10,616 Research and development 17,938 72 1 73 17,865 Restructuring costs 309 309 309 – Other (income) expense, net (24) (79) 45 (34) 10 Income Before Taxes 19,936 (2,519) (888) (45) (3,452) 23,388 Income Tax Provision (Benefit) 2,803 (461) (3) (135) (3) (10) (3) (519) (4) (1,125) 3,928 Net Income 17,133 (2,058) (753) (35) 519 (2,327) 19,460 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 17,117 (2,058) (753) (35) 519 (2,327) 19,444 Earnings per Common Share Assuming Dilution 6.74 $ (0.81) (0.30) (0.01) 0.21 (0.91) 7.65 $ Tax Rate 14.1% 16.8% Only the line items that are affected by non-GAAP adjustments are shown. The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non- GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Additionally, research and development expenses for the full year includes Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Represents benefits recorded in the fourth quarter and full year due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to federal income tax return years. The benefit recognized in the fourth quarter relates to the 2020 federal tax return year and the benefit recognized for the full year relates to both the 2020 and 2019 federal tax return years. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities MERCK & CO., INC., RAHWAY, N.J., USA FOURTH QUARTER AND FULL YEAR 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b Non-GAAP Certain Other Items Adjustment Subtotal 4 -- 5 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2025 2024 4Q Full Year 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,529 $15,806 $17,276 $16,400 $65,011 $15,775 $16,112 $16,657 $15,624 $64,168 5 4 1 2 PHARMACEUTICAL 13,638 14,050 15,611 14,843 58,142 14,006 14,408 14,943 14,042 57,400 6 4 1 1 Oncology Keytruda 7,205 7,956 8,142 8,337 31,641 6,947 7,270 7,429 7,836 29,482 6 5 7 7 Keytruda Qlex 5 35 40 - - - - Alliance Revenue – Lynparza (2) 312 370 379 389 1,450 292 317 337 365 1,311 7 4 11 10 Alliance Revenue – Lenvima (2) 258 265 258 272 1,053 255 249 251 255 1,010 7 6 4 4 Welireg 137 162 196 220 716 85 126 139 160 509 37 37 41 41 Alliance Revenue – Reblozyl (3) 119 107 136 164 525 71 90 100 110 371 48 48 41 41 Vaccines (4) Gardasil/Gardasil 9 1,327 1,126 1,749 1,031 5,233 2,249 2,478 2,306 1,550 8,583 -34 -35 -39 -39 ProQuad/M-M-R II/Varivax 539 609 684 619 2,451 570 617 703 594 2,485 4 3 -1 -2 Vaxneuvance 230 229 226 140 825 219 189 239 161 808 -13 -16 2 1 Capvaxive 107 129 244 279 759 47 50 97 * * * * RotaTeq 228 121 204 119 673 216 163 193 139 711 -14 -15 -5 -5 Pneumovax 23 41 38 45 42 166 61 59 68 74 263 -43 -44 -37 -37 Hospital Acute Care Bridion 441 461 439 499 1,841 440 455 420 449 1,764 11 11 4 4 Prevymis 208 228 266 275 978 174 188 208 215 785 28 26 25 23 Zerbaxa 70 74 81 87 312 56 62 64 70 252 24 23 24 24 Dificid 83 96 43 25 247 73 92 96 79 340 -68 -68 -27 -27 Cardiometabolic & Respiratory Winrevair 280 336 360 467 1,443 70 149 200 419 133 133 * * Alliance Revenue - Adempas/Verquvo (5) 106 123 112 129 470 98 106 102 109 415 18 18 13 13 Adempas (6) 68 80 82 83 312 70 72 72 73 287 14 9 9 6 Ohtuvayre 178 178 - - - - Virology Lagevrio 102 83 138 57 380 350 110 383 121 964 -53 -53 -61 -61 Isentress/Isentress HD 90 86 82 67 325 111 89 102 92 394 -27 -28 -18 -18 Delstrigo 67 83 77 79 306 56 60 65 69 249 15 9 23 20 Pifeltro 45 41 43 42 171 42 39 42 40 163 6 4 5 4 Neuroscience Belsomra 50 40 47 49 186 46 53 78 45 222 8 9 -16 -16 Immunology Simponi 184 172 189 543 -100 -100 Remicade 39 35 41 114 -100 -100 Diabetes (7) Januvia 549 372 382 302 1,604 419 405 278 232 1,334 30 30 20 21 Janumet 247 251 243 199 940 251 224 204 255 935 -22 -22 1 2 Other Pharmaceutical (8) 729 584 948 658 2,917 632 618 638 699 2,590 -6 -5 13 13 ANIMAL HEALTH 1,588 1,646 1,615 1,505 6,354 1,511 1,482 1,487 1,397 5,877 8 6 8 9 Livestock 924 961 1,023 987 3,896 850 837 886 889 3,462 11 9 13 14 Companion Animal 664 685 592 518 2,458 661 645 601 508 2,415 2 0 2 2 Other Revenues (9) 303 110 50 52 515 258 222 227 185 891 -71 -15 -42 -6 *200% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $876 million, $704 million, $703 million and $579 million in the first, second, third and fourth quarter of 2025, respectively, and $745 million, $715 million, $592 million and $546 million in the first, second, third and fourth quarter of 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $44 million, $43 million, $214 million and $135 million in the first, second, third and fourth quarter of 2025, respectively, and $38 million, $37 million, $39 million and $56 million in the first, second, third and fourth quarter of 2024, respectively. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95 million, $5 million, $11 million and $27 million in the first, second, third and fourth quarter of 2025, respectively, and $61 million, $15 million, $15 million and $15 million in the first, second, third and fourth quarter of 2024, respectively. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,607 million, $2,370 million, $3,370 million and $2,364 million in the first, second, third and fourth quarter of 2025, respectively, and $3,424 million, $3,656 million, $3,675 million and $2,693 million in the first, second, third and fourth quarter of 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in the Company's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES FOURTH QUARTER 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 4Q 2025 4Q 2024 % Change 4Q 2025 4Q 2024 % Change 4Q 2025 4Q 2024 % Change TOTAL SALES (1) $16,400 $15,624 5 $9,139 $8,188 12 $7,261 $7,436 -2 PHARMACEUTICAL 14,843 14,042 6 8,662 7,728 12 6,181 6,314 -2 Oncology Keytruda 8,337 7,836 6 4,892 4,841 1 3,445 2,996 15 Keytruda Qlex 35 - 33 - 2 - Alliance Revenue – Lynparza (2) 389 365 7 180 177 1 209 187 12 Alliance Revenue – Lenvima (2) 272 255 7 191 182 5 80 73 11 Welireg 220 160 37 181 146 24 39 14 170 Alliance Revenue – Reblozyl (3) 164 110 48 133 88 51 31 22 37 Vaccines (4) Gardasil/Gardasil 9 1,031 1,550 -34 406 380 7 625 1,170 -47 ProQuad/M-M-R II/Varivax 619 594 4 427 419 2 192 175 9 Capvaxive 279 50 * 258 49 * 21 0 * Vaxneuvance 140 161 -13 50 64 -22 90 96 -6 RotaTeq 119 139 -14 60 84 -28 59 55 8 Pneumovax 23 42 74 -43 8 19 -61 35 55 -37 Hospital Acute Care Bridion 499 449 11 451 382 18 49 67 -28 Prevymis 275 215 28 130 106 23 146 109 33 Zerbaxa 87 70 24 50 40 25 36 30 23 Dificid 25 79 -68 17 72 -76 8 7 13 Cardiometabolic & Respiratory Winrevair 467 200 133 432 192 125 35 9 * Ohtuvayre 178 - 178 - Alliance Revenue - Adempas/Verquvo (5) 129 109 18 112 105 7 17 5 * Adempas (6) 83 73 14 83 73 14 Virology Delstrigo 79 69 15 14 14 -1 65 55 19 Isentress/Isentress HD 67 92 -27 37 38 -3 30 53 -44 Lagevrio 57 121 -53 11 32 -65 45 88 -49 Pifeltro 42 40 6 26 26 -3 17 13 23 Neuroscience Belsomra 49 45 8 22 19 18 27 26 1 Diabetes (7) Januvia 302 232 30 180 41 * 122 191 -36 Janumet 199 255 -22 57 91 -37 142 164 -14 Other Pharmaceutical (8) 658 699 -6 126 121 4 531 581 -9 ANIMAL HEALTH 1,505 1,397 8 448 444 1 1,056 953 11 Livestock 987 889 11 209 203 3 777 686 13 Companion Animal 518 508 2 239 241 -1 279 267 4 Other Revenues (9) 52 185 -71 29 16 81 24 169 -86 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Total Diabetes sales were $579 million and $546 million on a global basis in the fourth quarter of 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $135 million and $56 million on a global basis in the fourth quarter of 2025 and 2024, respectively. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $27 million and $15 million in the fourth quarter of 2025 and 2024, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,364 million and $2,693 million on a global basis in the fourth quarter of 2025 and 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES FULL YEAR 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International Full Year 2025 Full Year 2024 % Change Full Year 2025 Full Year 2024 % Change Full Year 2025 Full Year 2024 % Change TOTAL SALES (1) $65,011 $64,168 1 $36,510 $32,277 13 $28,501 $31,891 -11 PHARMACEUTICAL 58,142 57,400 1 34,409 30,290 14 23,733 27,110 -12 Oncology Keytruda 31,641 29,482 7 18,829 17,872 5 12,812 11,610 10 Keytruda Qlex 40 - 38 - 2 - Alliance Revenue – Lynparza (2) 1,450 1,311 11 683 626 9 767 685 12 Alliance Revenue – Lenvima (2) 1,053 1,010 4 737 705 4 316 305 4 Welireg 716 509 41 603 466 29 113 43 161 Alliance Revenue – Reblozyl (3) 525 371 41 432 303 42 93 68 37 Vaccines (4) Gardasil/Gardasil 9 5,233 8,583 -39 2,641 2,425 9 2,592 6,158 -58 ProQuad/M-M-R II/Varivax 2,451 2,485 -1 1,885 1,919 -2 566 566 0 Vaxneuvance 825 808 2 459 461 0 366 347 5 Capvaxive 759 97 * 730 96 * 29 1 * RotaTeq 673 711 -5 426 472 -10 246 239 3 Pneumovax 23 166 263 -37 21 56 -63 146 207 -30 Hospital Acute Care Bridion 1,841 1,764 4 1,631 1,401 16 209 363 -42 Prevymis 978 785 25 475 371 28 503 414 21 Zerbaxa 312 252 24 186 146 28 126 106 18 Dificid 247 340 -27 202 303 -33 45 37 20 Cardiometabolic & Respiratory Winrevair 1,443 419 * 1,358 408 * 85 11 * Alliance Revenue - Adempas/Verquvo (5) 470 415 13 421 388 8 49 27 81 Adempas (6) 312 287 9 312 287 9 Ohtuvayre 178 - 178 - Virology Lagevrio 380 964 -61 101 176 -43 278 787 -65 Isentress/Isentress HD 325 394 -18 181 185 -3 144 209 -31 Delstrigo 306 249 23 56 56 1 250 193 29 Pifeltro 171 163 5 111 113 -1 59 50 18 Neuroscience Belsomra 186 222 -16 82 72 13 104 150 -31 Immunology Simponi 543 -100 543 -100 Remicade 114 -100 114 -100 Diabetes (7) Januvia 1,604 1,334 20 999 469 113 605 865 -30 Janumet 940 935 1 268 161 66 672 774 -13 Other Pharmaceutical (8) 2,917 2,590 13 676 640 6 2,244 1,951 15 ANIMAL HEALTH 6,354 5,877 8 1,953 1,861 5 4,401 4,016 10 Livestock 3,896 3,462 13 807 732 10 3,089 2,729 13 Companion Animal 2,458 2,415 2 1,146 1,129 2 1,312 1,287 2 Other Revenues (9) 515 891 -42 148 126 17 367 765 -52 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Total Diabetes sales were $2,862 million and $2,599 million on a global basis for December YTD 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $436 million and $170 million on a global basis for December YTD 2025 and 2024, respectively. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $138 million and $106 million on a global basis for December YTD 2025 and 2024, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $10,711 million and $13,448 million on a global basis for December YTD 2025 and 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2025 2024 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year TOTAL PHARMACEUTICAL $13,638 $14,050 $15,611 $14,843 $58,142 $14,006 $14,408 $14,943 $14,042 $57,400 6 1 United States 7,927 8,328 9,493 8,662 34,409 6,936 7,399 8,227 7,728 30,290 12 14 % Pharmaceutical Sales 58.1% 59.3% 60.8% 58.4% 59.2% 49.5% 51.4% 55.1% 55.0% 52.8% Europe (1) 2,384 2,551 2,675 2,839 10,449 2,555 2,572 2,620 2,498 10,246 14 2 % Pharmaceutical Sales 17.5% 18.2% 17.1% 19.1% 18.0% 18.2% 17.9% 17.5% 17.8% 17.9% Japan 651 604 693 684 2,632 802 664 919 813 3,199 -16 -18 % Pharmaceutical Sales 4.8% 4.3% 4.4% 4.6% 4.5% 5.7% 4.6% 6.2% 5.8% 5.6% Latin America 589 654 691 644 2,578 601 661 730 680 2,672 -5 -4 % Pharmaceutical Sales 4.3% 4.7% 4.4% 4.3% 4.4% 4.3% 4.6% 4.9% 4.8% 4.7% Asia Pacific (other than China and Japan) 535 609 593 586 2,323 580 595 669 612 2,457 -4 -5 % Pharmaceutical Sales 3.9% 4.3% 3.8% 4.0% 4.0% 4.1% 4.1% 4.5% 4.4% 4.3% China (2) 668 407 377 364 1,816 1,744 1,790 996 864 5,394 -58 -66 % Pharmaceutical Sales 4.9% 2.9% 2.4% 2.5% 3.1% 12.5% 12.4% 6.7% 6.2% 9.4% Eastern Europe/Middle East/Africa 435 451 365 348 1,598 395 353 400 348 1,495 0 7 % Pharmaceutical Sales 3.2% 3.2% 2.3% 2.3% 2.7% 2.8% 2.4% 2.7% 2.5% 2.6% Canada 125 135 134 153 547 138 143 133 144 558 6 -2 % Pharmaceutical Sales 0.9% 1.0% 0.9% 1.0% 0.9% 1.0% 1.0% 0.9% 1.0% 1.0% Other 324 311 590 563 1,790 255 231 249 355 1,089 59 64 % Pharmaceutical Sales 2.4% 2.1% 3.9% 3.8% 3.2% 1.9% 1.6% 1.5% 2.5% 1.7% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. (2) Gardasil/Gardasil 9 sales in China were $193 million, $0, $0 and $0 in the first, second, third and fourth quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first, second, third, and fourth quarter of 2024, respectively. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 4Q25 4Q24 Full Year 2025 Full Year 2024 Interest income (69) $ (146) $ (343) $ (415) $ Interest expense 412 328 1,357 1,271 Exchange losses 99 49 323 227 Loss (income) from investments in equity securities, net (1) 196 156 (368) (14) Net periodic defined benefit plan (credit) cost other than service cost (163) (157) (615) (633) Other, net (43) (104) (203) (460) Total 432 $ 126 $ 151 $ (24) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC., RAHWAY, N.J., USA OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --